Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A phase 2 trial shows promise for durvalumab combined with chemotherapy in resectable non-small cell lung cancer. Over 92% of patients proceeded to curative-intent treatment — either surgery or chemoradiotherapy — with no new safety red flags. The results, presented at WCLC 2026, support this perioperative immunotherapy approach as a viable path forward for early-stage NSCLC.
A global phase 2 trial called MDT-BRIDGE is turning heads in lung cancer care. The study tested perioperative durvalumab (an immunotherapy) combined with chemotherapy in 142 patients with resectable or borderline resectable stage IIB–IIIB non-small cell lung cancer (NSCLC). Results presented at WCLC 2026 showed that the vast majority of patients were able to move forward with curative-intent treatment — a meaningful win for a patient population that often faces limited options.
The approach worked in two tracks: patients whose disease remained resectable after initial treatment went on to surgery, while those with unresectable disease received chemoradiotherapy (CRT). Both groups then received durvalumab as adjuvant or consolidation therapy. Encouragingly, no new safety signals emerged, and the most common side effects were nausea and anemia.
By the Numbers:
Why it matters: These results suggest that a multidisciplinary team-guided, immunotherapy-based perioperative strategy can get most early-stage NSCLC patients to curative treatment — potentially improving long-term survival outcomes in a disease where early intervention is critical.
